VetDC announces commercial launch of canine lymphoma drug

Tuesday April 4, 2017 0 comments Tags: Fort Collins, VetDC, Tanovea-CA1, Terry Opgenorth

FORT COLLINS -- VetDC, Inc., a veterinary cancer therapeutics company, announced that TANOVEA™-CA1 is now commercially available in the U.S. for purchase by licensed veterinarians.VetDC_logoUSE

TANOVEA-CA1 was recently granted conditional approval by the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM), making TANOVEA-CA1 the first and only new animal drug indicated for the treatment of lymphoma in dogs, the company said.

“VetDC stands out among an elite group of pure-play animal health startups that have advanced a novel program from development through commercialization,” said Dr. Terry Opgenorth, VP of CSU Ventures and VetDC co-founder.

“We believe TANOVEA-CA1 represents a significant breakthrough in the rapidly evolving field of veterinary oncology.”

“We are ecstatic to hear the news of TANOVEA-CA1’s commercial availability,” said Dr. Craig Clifford, a board-certified veterinary oncologist and clinical investigator at Hope Veterinary Specialists in Malvern, PA.

“Based on our first-hand experience as part of a robust clinical trials program, we believe TANOVEA-CA1 has the potential to become a cornerstone for the treatment of lymphoma in dogs.”

VetDC said TANOVEA-CA1 (rabacfosadine for injection) is a novel small molecule drug designed to preferentially target and attack rapidly dividing cancer cells implicated in lymphoma.

TANOVEA-CA1 has demonstrated anti-tumor activity in both naïve and relapsed canine lymphoma cases, with a generally well-tolerated safety profile, the company said.

TANOVEA-CA1 is administered intravenously every three weeks for up to five doses.

VetDC said TANOVEA-CA1 is conditionally approved by the FDA for the treatment of canine lymphoma pending a full demonstration of effectiveness.

For additional prescribing, safety and ordering information, visit tanovea.com.